FDA Cancels Panel Meeting on Merck Surgery Drug

March 13, 2015 9:23 PM

2 0

The U.S. Food and Drug Administration has canceled an advisory committee's meeting to review Merck & Co.'s sugammadex, further delaying the surgery drug.

Merck said the agency intends to conduct more inspections of sites involved in a study of patient hypersensitivity to the drug. Merck said it expects to receive a letter from the FDA by April 22, the targeted action date, saying the application is not yet ready for approval. Merck said it would cont...

Read more

To category page